Loading clinical trials...
Loading clinical trials...
A Phase I, Open-label, Parallel-group Study to Evaluate the Single-dose Pharmacokinetics of Palovarotene in Male and Female Participants With Moderate and Severe Hepatic Impairment and Matched Participants With Normal Hepatic Function
Conditions
Interventions
Palovarotene
Palovarotene
+1 more
Locations
4
United States
ERG - Clinical Pharmacology of Miami
Miami, Florida, United States
Orlando Clinical Research Center
Orlando, Florida, United States
American Research Corporation/Texas Liver Institute
San Antonio, Texas, United States
Pinnacle Clinical Research
San Antonio, Texas, United States
Start Date
March 14, 2025
Primary Completion Date
February 6, 2026
Completion Date
February 6, 2026
Last Updated
April 1, 2026
NCT07470866
NCT00104325
NCT07221448
NCT07388667
NCT06637865
NCT07118891
Lead Sponsor
Ipsen
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions